Hideyuki Ikematsu

Hideyuki Ikematsu

Auto-generated profile, based on publicly available information

Hideyuki Ikematsu

Japan Physicians Association, Japan

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2005 in International Immunology
Verified
Journal Article
Open access
PDF file
YCYong Chong
Yong Chong
HIHideyuki Ikematsu
Hideyuki Ikematsu
KYKouzaburo Yamaji
Kouzaburo Yamaji
MNMika Nishimura
Mika Nishimura
SNShigeki Nabeshima
Shigeki Nabeshima
JHJun Hayashi
Jun Hayashi
To investigate age-related alterations in human humoral immunity, we analyzed the quantity and quality of peripheral B cell subsets, CD27-negative (CD27−) and CD27-positive (CD27+) B cells, by flow cytometry analysis in 54 aged individuals (mean age ± SE, 74.6 ± 0.7 years) and 30 young individuals (mean age ± SE, 26.1 ± 0.5 years). CD27− and CD27+ B cells are regarded as naive and memory B cells, respectively. CD38, Ki-67, CD95 and bcl-2 were used as activation, proliferation and apoptotic markers. Susceptibility to apoptosis was evaluated by cell size and annexin-V binding in culture cells. The percentage of CD27+ B cells was significantly lower in aged (mean, 19.2%) individuals than that in young individuals (mean, 28.2%). The opposite was true for CD27− B cells (mean, 80.8% in aged and 71.8% in young) (P < 0.01). The absolute number of CD27+ B cells in aged individuals was significantly less than the number of CD27− B cells. The CD27+ B cells from aged individuals showed little susceptibility to apoptosis, although CD95 expression on the CD27+ B cells was significantly higher in the aged individuals than in the young individuals (P < 0.05). The CD38 and bcl-2 expression on the CD27− B cells was significantly higher in the aged individuals than in the young individuals (P < 0.05). In addition, the CD27− B cells from the aged individuals showed a decreased susceptibility to apoptosis compared with that of the young individuals. These findings suggested that human aging leads to both quantitative and qualitative alterations in the peripheral B cell developmental system, including memory and naive B cell balance and their surface phenotypes.

1 October 2011 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
HIHideyuki Ikematsu
Hideyuki Ikematsu
NKNaoki Kawai
Naoki Kawai
Oseltamivir and zanamivir are well-established and well-researched drugs for the treatment of influenza in Japan and the rest of the world. A new neuraminidase inhibitor, laninamivir octanoate, has been approved for use in Japanese clinics. Laninamivir octanoate is an inhaled drug with unique characteristics. The inhaled laninamivir octanoate is converted into its active form, laninamivir, in the lungs where a high concentration persists for a long period of time. The concentration of laninamivir exceeds the level necessary for influenza virus replication inhibition for at least 5 days, thus influenza can be treated with a single administration. The drug is delivered using one device requiring four inhalations for children and two devices requiring eight inhalations for adults. Clinical trials have shown comparable efficacy for laninamivir octanoate and oseltamivir. Laninamivir octanoate also displayed a sufficient antiviral effect to treat infection with H275Y-mutated oseltamivir-resistant virus. Laninamivir octanoate has displayed clinical efficacy comparable to that of oseltamivir and zanamivir against the H1N1 pandemic influenza strain from 2009, seasonal H3N2 influenza and influenza B viruses. The prophylactic efficacy of laninamivir octanoate has been shown in animal models. The effectiveness of laninamivir against the highly pathogenic avian influenza virus H5N1 has also been shown in vitro and in animal models. A major clinical benefit of this drug is that the single administration is very convenient for both the patient and doctor, which leads to improved compliance. Furthermore, this drug shows promise for the treatment of influenza in future pandemics.

5 June 1996 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
KTKeitaro Tanaka
Keitaro Tanaka
HIHideyuki Ikematsu
Hideyuki Ikematsu
THTomio Hirohata
Tomio Hirohata
SKSeizaburo Kashiwagi
Seizaburo Kashiwagi
Background:Although hepatitis C virus (HCV) infection is recognized as an important risk factor for hepatocellular carcinoma (HCC), the strength of this association has been inconsistent. In addition, the role of specific HCV genotypes in HCC progression has not yet been determined.Purpose:We conducted a case—control study to estimate the relative risk (RR) of HCC in relation to HCV infection among residents of the Fukuoka Prefecture, where HCC risk is among the highest in Japan, and to examine whether the risk differs according to HCV genotypes and/or HCV RNA titers.Methods:Stored serum samples obtained from 91 patients with HCC and 410 healthy control subjects, who had been frequency matched to the patients with regard to sex and age, were tested for antibodies to HCV by use of second-generation immunoradiometric and immunoblot assays. The presence of serum HCV RNA and of specific HCV genotypes was determined by use of polymerase chain reaction-based assays, and HCV RNA titers were measured by use of a branched DNA assay.Results:Antibodies to HCV were detected in 71 patients (78.0%) and in 30 control subjects (7.3%), of whom 57 patients and 25 control subjects had serum HCV RNA. One patient was positive for HCV RNA but not for antibodies to HCV. The sex-and age-adjusted RR of HCC among individuals positive for antibodies to HCV was estimated to be 53.7 (95% confidence interval [CI] = 27.1–106.2). Antibodies to HCV were much more prevalent among patients negative for serum hepatitis B surface antigen (HBsAg) (69 of 72, 95.8%) than among HBsAg-positive patients (two of 19, 10.5%); the RR increased to 339.6 (95% CI = 96.5–1195.8) in the separate analysis of HBsAg-negative subjects. The most frequent genotype among HCV RNA-positive subjects was type lb (also called type II) (found in 49 [86.0%] of 57 patients and in 15 [60.0%] of 25 control subjects); individuals with type 1b infection experienced a significantly elevated risk (RR = 3.8; 95% CI = 1.0–13.9) compared with the risk observed for individuals with type 2a (also called type III) infection. No statistically significant association between HCV RNA titers and HCC was evident.Conclusions:HCV infection, particularly type 1b infection, plays an important role in the development of HCC among the study population. We estimated that approximately 78% (95% CI = 69%86%) of the HCCs that occur in this high-risk area are attributable to HCV infection, if we assume that the patients in this study were representative population samples.Implications:Further studies are needed to clarify potential risk factors, including specific HCV genotypes, for progression to HCC among HCV carriers.

28 June 2019 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
LOLidia Oostvogels
Lidia Oostvogels
THThomas C. Heineman
Thomas C. Heineman
RJRobert W. Johnson
Robert W. Johnson
MLMyron J. Levin
Myron J. Levin
JMJanet E. McElhaney
Janet E. McElhaney
Anthony L. CunninghamAnthony L. Cunningham
Anthony L. Cunningham
In two pivotal efficacy studies (ZOE-50; ZOE-70), the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster (HZ). Adults aged ≥50 or ≥70 years (ZOE-50 [NCT01165177]; ZOE-70 [NCT01165229]) were randomized to receive 2 doses of RZV or placebo 2 months apart. Vaccine efficacy and safety were evaluated post-hoc in the pooled (ZOE-50/70) population according to the number and type of selected medical conditions present at enrollment. At enrollment, 82.3% of RZV and 82.7% of placebo recipients reported ≥1 of the 15 selected medical conditions. Efficacy against HZ ranged from 84.5% (95% Confidence Interval [CI]: 46.4–97.1) in participants with respiratory disorders to 97.0% (95%CI: 82.3–99.9) in those with coronary heart disease. Moreover, efficacy remained >90% irrespective of the number of selected medical conditions reported by a participant. As indicated by the similarity of the point estimates, this post-hoc analysis suggests that RZV efficacy remains high in all selected medical conditions, as well as with increasing number of medical conditions. No safety concern was identified by the type or number of medical conditions present at enrollment.

1 November 2010 in Human Vaccines
Verified
Journal Article
Closed access
HIHideyuki Ikematsu
Hideyuki Ikematsu
HNHideaki Nagai
Hideaki Nagai
MKMasahiro Kawashima
Masahiro Kawashima
YKYasunobu Kawakami
Yasunobu Kawakami
KTKazuyoshi Tenjinbaru
Kazuyoshi Tenjinbaru
FRFrançois Roman
François Roman
We are grateful to the New York Medical College, New York for providing the vaccine virus strain and to the National Institute for Biological Standards and Control (NIBSC, UK) and the Therapeutic G...

1 January 2015 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
HIHideyuki Ikematsu
Hideyuki Ikematsu
NKNaoki Kawai
Naoki Kawai
NINorio Iwaki
Norio Iwaki
SKSeizaburo Kashiwagi
Seizaburo Kashiwagi